Trade Acorda Therapeutics

Acorda Therapeutics, Inc. is an American biotechnology company based in Ardsley, New York. The company is developing treatments that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets inbrija (levodopa inhaler powder) and Ampyra (Dalvamedin) in the United States. Inbria (levodopa inhalation powder) administered by inhalation is referred to as intermittent treatment of episodes in patients with Parkinson's disease currently taking carbidupa/levodopa. Inpreria has been approved by the FDA and the European Union. in September 2014, the company acquired Civitas treatment for US$525 million, and acquired the third-stage Parkinson's drug, CVT-301, cvt-427 migraine and arcus pulmonary birth system rights. This Arcos technology allows to administer the drug by inhalation. The drug approved by the FDA Inbrija (levodopa inhaling powder) and the clinical phase of the drug CVT-427 (zolmitriptan) is currently using ARCUS technology to deliver the drug.